Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a current biopsy-confirmed NASH within 6 months of screening or a suspected diagnosis of NAFLD/NASH~* Screening magnetic resonance imaging-proton density fat fraction (MRI-PDFF) with ≥10% liver steatosis~* Fasting serum low density lipoprotein-cholesterol (LDL-C) \>130 mg/dL at Screening, \>110 mg/dL on lipid-lowering medications~Key Exclusion Criteria:~* Body mass index (BMI) \<25 kg/m2~* Fibrosis-4 index (Fib-4) \>2.6~* Any of the following laboratory abnormalities:~  1. alanine aminotransferase (ALT) \>5 × upper limit of normal (ULN) or aspartate aminotransferase (AST) \>5 × ULN~ 2. International normalized ratio (INR) ≥1.3, unless on anticoagulant therapy~ 3. Total bilirubin \>ULN, except with an established diagnosis of Gilbert's syndrome~ 4. Platelet count less than the lower limit of normal (LLN)~ 5. Creatinine clearance as calculated by the modification of diet in renal disease (MDRD) estimated glomerular filtration rate (eGFR) equation \<60 mL/min~* Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) \>9.5%~* Clinical hyperthyroidism or hypothyroidism or screening hormone results pointing to thyroid dysfunction.~* Uncontrolled hypertension~* Participants with known intolerance to MRI or with conditions contraindicated for MRI procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elobixibat (Type: EXPERIMENTAL): Elobixibat 5 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).